TG Therapeutics, Inc. Announces Data Presentations At The Upcoming 58th American Society Of Hematology Annual Meeting

NEW YORK, Nov. 03, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced that updated data for TGR-1202, the Company's once-daily PI3K delta inhibitor, and TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody, have been selected for presentation at the upcoming 58 th American Society of Hematology (ASH) annual meeting, to be held December 3-6, 2016, at the San Diego Convention Center in San Diego, California.

"We are looking forward to an exciting ASH conference as we continue to present data on the differentiation between TGR-1202 and the first generation PI3K delta inhibitors.  With three oral presentations and three poster presentations it is clear the strength of TGR-1202, and our overall UNITY program, is starting to be noticed by leaders in the treatment of B-cell malignancies.  We have seen scientific and clinical interest in our programs continue to grow, and notably all three of the oral presentations at this coming ASH meeting resulted from independent investigator driven interest in working with TGR-1202.  We look forward to sharing this data at the upcoming meeting and expanding on our investigator initiated collaborations while we continue to drive our registration-directed trials toward pivotal data in 2017, potentially leading to our first approval in 2018," stated Michael S. Weiss, the Company's Executive Chairman and Interim CEO. Presentations at the ASH 2016 meeting include the following:

Oral Presentations:
  • Title: Silencing c-Myc Translation as a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies
    • Abstract Number: 291
    • Oral Session: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Cell Signaling
    • Date and Time:  Sunday, December 4, 2016; 7:30 AM - 9:00 AM PT
    • Presentation Time: 8:00 AM PT
    • Location: San Diego Convention Center, Room 5AB
    • Presenter: Changchun (George) Deng, MD, PhD, Columbia University, New York, NY
  • Title: TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study
    • Abstract Number: 641
    • Oral Session: 642. CLL: Therapy, excluding Transplantation: Targeted Therapy: Novel Agents and Combinations
    • Date and Time:  Monday, December 5, 2016; 7:00 AM - 8:30 AM PT
    • Presentation Time: 8:00 AM PT
    • Location: San Diego Convention Center, Room 5AB
    • Presenter: Matthew S. Davids, MD, Dana Farber Cancer Institute, Boston, MA 
  • Title: Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kd Inhibitor TGR-1202 in Myelofibrosis
    • Abstract Number: 1125
    • Oral Session: 634. Myeloproliferative Syndromes: Clinical: Clinical Trials with JAK Inhibitors
    • Date and Time:  Monday, December 5, 2016; 4:30 PM - 6:00 PM PT
    • Presentation Time: 5:00 PM PT
    • Location: Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17
    • Presenter: Tamara Kay Moyo, MD, PhD, Vanderbilt-Ingram Cancer Center, Nashville, TN

If you liked this article you might like

Biotech M&A: Who's Next After Gilead-Kite?

Lockheed Martin, TG Therapeutics, HD Supply: 'Mad Money' Lightning Round

Bitter Battle Between Growth and Value: Cramer's 'Mad Money' Recap (Wednesday 6/21/17)

Biotech Needs a Shot in the Arm